Transplantation of skin mesenchymal stem cells attenuated AngII-induced hypertension and vascular injury
Creators
- 1. The State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 (China)
- 2. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031 (China)
Description
Highlights: • Injection of S-MSCs ameliorated AngII-induced hypertension and vascular injury. • S-MSCs attenuated hypertension through modulating Th17 cell differentiation and macrophage M2 polarization. • The CXCR4/SDF-1 axis could be involved in the immunomodulatory effect of S-MSCs. Skin mesenchymal stem cells (S-MSCs) revealed an important immunomodulatory activity to markedly suppress the formation of the atherosclerosis (AS) plaque by modulating macrophages, and also inhibit the development of experimental autoimmune encephalomyelitis (EAE) by regulating T helper 17 (Th17) cell differentiation. Macrophages and Th17 cells play important roles in hypertension. However, it remains unclear whether S-MSCs are capable of improving angiotensin (AngII)-induced hypertension by acting on inflammatory cells. Therefore, we studied a direct effect of S-MSC treatment on an AngII-induced hypertensive mouse model. Twenty-seven C57BL/6 (WT) mice were divided into three groups: Control group (WT-NC), AngII-infused group (WT-AngII), and S-MSC treatment group (WT-AngII + S-MSCs). In contrast to WT-AngII group, systolic blood pressure (SBP) and vascular damage were strikingly attenuated after tail-vein injection of S-MSCs. Numbers of Th17 cells in mouse peripheral blood of S-MSC treated group were significantly decreased, and IL-17 mRNA and protein levels were also reduced in the aorta and serum compared with WT-AngII group. Furthermore, macrophages in S-MSC treated group were switched to a regulatory profile characterized by a low ability to produce pro-inflammatory cytokine TNF-α and a high ability to produce anti-inflammatory cytokines Arg1 and IL-10. Mechanistically, we found that S-MSCs inhibited Th17 cell differentiation and induced M2 polarization. Moreover, we found proliferation and migration of S-MSCs were elevated, and expression of CXCR4, the receptor for Stromal derivated factor −1(SDF-1), was markedly increased in lipopolysaccharide (LPS)- stimulated S-MSCs. Given that SDF-1 expression was increased in the serum and aorta in AngII- induced hypertensive mice, the immunomodulatory effects exerted by S-MSCs involved the CXCR4/SDF-1 signaling. Collectively, our data demonstrated that S-MSCs attenuated AngII-induced hypertension by inhibiting Th17 cell differentiation and by modulating macrophage M2 polarization, suggesting that S-MSCs potentially have a role in stem cell based therapy for hypertension.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2018.02.180Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2018.02.180;
- PII
- S0006291X18304261;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 497
- Journal Issue
- 4
- Journal Page Range
- p. 1068-1075
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 54056606
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ANGIOTENSIN; AORTA; ARTERIOSCLEROSIS; BLOOD; LIPOPOLYSACCHARIDES; LYMPHOKINES; MACROPHAGES; MESSENGER-RNA; MICE
- Descriptors DEC
- ANIMAL CELLS; ANIMALS; ARTERIES; BIOLOGICAL MATERIALS; BLOOD VESSELS; BODY; BODY FLUIDS; CARBOHYDRATES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CONNECTIVE TISSUE CELLS; DISEASES; DRUGS; GLOBULINS; GROWTH FACTORS; LIPIDS; MAMMALS; MATERIALS; MITOGENS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PHAGOCYTES; POLYSACCHARIDES; PROTEINS; RNA; RODENTS; SACCHARIDES; SOMATIC CELLS; VASCULAR DISEASES; VASOCONSTRICTORS; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2018 Elsevier Inc. All rights reserved.